Table 1 Baseline Characteristics of the Study Subjects:
| Â | COPD non-smokers (N = 13) | COPD smokers (N = 8) | Control non-smokers (N = 12) | Control smokers (N = 9) |
|---|---|---|---|---|
Mean age (95% CI) | 72.8 (69.4-76.3) | 62.3 (58.7 - 65.8) | 66.7 (62.4-70.9) | 56.4 (52.7-60.1) |
Female Gender | 7 (54%) | 5 (63%) | 7 (58%) | 6 (67%) |
Mean BMI (95% CI) | 28.3 (25.4-31.2) | 25.5 (20.9-30.2) | 25.8 (23.9-27.7) | 26.0 (24.5-27.6) |
Pack Years (95% CI) | 44.5 (33.7-55.2) | 53.8 (44.5-63.0) | 0 | 29.3 (22.0-36.7) |
Post-bronchodilator FEV1% predicted | 46 (39 - 53) | 44 (33 - 54) | 101 (92-111) | 102 (93-111) |
GOLD Stage II | 6 (46%) | 3 (38%) | 0 | 0 |
GOLD Stage III | 6 (46%) | 3 (38%) | 0 | 0 |
GOLD Stage IV | 1 (8%) | 2 (25%) | 0 | 0 |
History of Chronic Bronchitis | 7 (54%) | 8 (100%) | 0 (0%) | 3 (33%) |
Total lung capacity % predicted | 122 (108 - 136) | 117 (106-127) | 103 (96-110) | 106 (99-114) |
Residual volume % predicted | 172 (132 - 211) | 176 (150-201) | 93 (81-104) | 94 (81-108) |
Diffusion capacity (DLCO % predicted | 64 (56 - 73) | 64 (50-78) | 86 (82-90) | 78 (71-84) |
Baseline Dyspnea Index Score (95% CI) | 6.0 (4.7 - 7.4) | 6.5 (4.7 - 8.2) | 11.6 (11.2-11.9) | 10.9 (10.1-11.6) |
Use of inhaled corticosteroids | 10 (77%) | 7 (88%) | 0 | 0 |